# Nirali N. Shah

Source: https://onco.cc/people/nirali-shah/  
OnCo record `nirali-shah` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nirali Shah developed CD22 CAR-T for children whose leukaemia escaped CD19 therapy.

## Summary

Nirali N. Shah is Head of the Hematologic Malignancies Section in the Pediatric Oncology Branch at the National Cancer Institute. She is a paediatric leukaemia specialist known for developing CD22-directed CAR-T for children whose acute lymphoblastic leukaemia escaped CD19 therapy, addressing CD19-negative relapse after tisagenlecleucel and blinatumomab. Her selected paper reports that CD22-targeted CAR T cells induce remission in B-cell acute lymphoblastic leukaemia that is naive or resistant to CD19-targeted CAR immunotherapy. She leads paediatric CAR-T trials at NCI.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Head, Hematologic Malignancies Section, Pediatric Oncology Branch
- Specialisms: Paediatric leukaemia; CAR-T; CD22

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Nirali_N._Shah
- NCI CCR profile: https://ccr.cancer.gov/staff-directory/nirali-n-shah
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Shah%20NN%5BAuthor%5D

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD22](https://onco.cc/targets/cd22/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [NCI Center for Cancer Research (intramural programme)](https://onco.cc/institutions/nci-ccr/)

---
JSON: https://onco.cc/api/v1/entities/nirali-shah.json